MediciNova, Inc.

NasdaqGM:MNOV 株式レポート

時価総額：US$67.9m

MediciNova マネジメント

マネジメント 基準チェック /24

MediciNovaの CEO はYuichi Iwakiで、 Jan2000年に任命され、 の在任期間は 26.58年です。 の年間総報酬は$ 1.74Mで、 37.9%給与と62.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.22%を直接所有しており、その価値は$ 1.51M 。経営陣と取締役会の平均在任期間はそれぞれ10.1年と6.5年です。

主要情報

Yuichi Iwaki

最高経営責任者

US$1.7m

報酬総額

CEO給与比率37.85%
CEO在任期間26.6yrs
CEOの所有権2.2%
経営陣の平均在職期間10.1yrs
取締役会の平均在任期間6.5yrs

経営陣の近況

Recent updates

分析記事 • Aug 28

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Apr 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
分析記事 • Nov 27

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jul 11

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Mar 18

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Oct 12

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 15

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova (NASDAQ:MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma. The new patent is expected to expire no earlier than February 2039, the company said in a Sept. 14 press release. Glioblastoma is a type of cancer that can occur in the brain or spinal cord. The allowed claims cover a method of treating a patient with glioblastoma or recurrent glioblastoma wherein a patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents. "Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone," said MediciNova Chief Medical Officer Kazuko Matsuda.
Seeking Alpha • Aug 16

MediciNova's MN-166 to be part of study to treat Long COVID

MediciNova (NASDAQ:MNOV) said it plans to participate in a grant-funded clinical trial, dubbed RECLAIM, to evaluate MN-166 (ibudilast) and other therapies for treating Long COVID. The company added that it reached an agreement to collaborate with the University Health Network.
Seeking Alpha • Jul 22

MediciNova begins study of parenteral formulation of MN-166

MediciNova (NASDAQ:MNOV) said it started a first-in-human study of a new parenteral formulation of MN-166 (ibudilast). The company said the newly developed MN-166 (ibudilast) formulation will provide an additional option besides the current oral formulation. "With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166," said MediciNova Chief Medical Officer Kazuko Matsuda. In April, the company reported data from a phase 2 trial of MN-166 for alcohol use disorder, showing that the drug reduced alcohol craving on non-drinking days.
Seeking Alpha • Jun 30

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova (NASDAQ:MNOV) said on Wednesday that a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for its small molecule candidate MN-166 (ibudilast). Under the partnership with BARDA, the company will repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). The contract was amended to extend the period of performance until March 2023. BARDA, a division of the U.S. Department of Health and Human Services will fund the proof-of-concept studies in preclinical models of chlorine gas-induced acute lung injury. The project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority. Last year in March, MediciNova jumps on BARDA partnership for Ibudilast development. Shares are up 2.75% after-hours.
分析記事 • Mar 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
分析記事 • Nov 23

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 31

MediciNova: The Pain Of A Positive Outlook

MediciNova reported blasé Q2 2021 earnings on 08/12/2021. MediciNova's core pipeline consists of two candidate therapies being developed in treatment of eleven indications. MediciNova's MS program is a high potential, late stage program which has been in stall mode. MediciNova has operated under less financial strain than expected for a company with its advanced pipeline.
Seeking Alpha • Jun 21

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

MediciNova (MNOV) soars 30.6% premarket after announcing positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder ((AUD)), published in Nature’s Translational Psychiatry. The Phase 2 trial evaluated the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in individuals with AUD. A total of 52 patients were enrolled. Key results include: Ibudilast did not have a significant effect on negative mood.Ibudilast, relative to placebo, reduced the odds of heavy drinking across time
分析記事 • May 15

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

CEO報酬分析

MediciNova の収益と比較して、Yuichi Iwaki の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2026n/an/a

-US$11m

Mar 31 2026n/an/a

-US$12m

Dec 31 2025US$2mUS$657k

-US$12m

Sep 30 2025n/an/a

-US$12m

Jun 30 2025n/an/a

-US$12m

Mar 31 2025n/an/a

-US$11m

Dec 31 2024US$1mUS$657k

-US$11m

Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$1mUS$657k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$620k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$3mUS$596k

-US$10m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$3mUS$587k

-US$14m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$12m

Mar 31 2020n/an/a

-US$11m

Dec 31 2019US$4mUS$572k

-US$13m

報酬と市場: Yuichiの 総報酬 ($USD 1.74M ) は、 US市場 ($USD 654.65K ) の同規模の企業の平均を上回っています。

報酬と収益: Yuichiの報酬は増加しましたが、会社は利益を上げていません。

CEO

Yuichi Iwaki (76 yo)

26.6yrs
在職期間
US$1,736,711
報酬

Dr. Yuichi Iwaki, M.D., Ph D., is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006 and as Chairman. Dr. Iwaki served as Acting Principal Financial Off...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Yuichi Iwaki
Co-Founder26.6yrsUS$1.74m2.22%
$ 1.5m
Kazuko Matsuda
Senior VP14.9yrsUS$1.33m0.66%
$ 445.7k
David Crean
Chief Business Officer5.3yrsUS$120.00k0%
$ 0
Jason Kruger
CFO & Principal Financial Officer4.2yrsデータなしデータなし
10.1yrs
平均在職期間
60.5yo
平均年齢

経験豊富な経営陣: MNOVの経営陣は経験豊富で経験豊富です（平均在職期間は10.1年）。

取締役

名称ポジション在職期間報酬所有権
Yuichi Iwaki
Co-Founder25.9yrsUS$1.74m2.22%
$ 1.5m
Kazuko Matsuda
Senior VP7.1yrsUS$1.33m0.66%
$ 445.7k
Hideki Nagao
Independent Director8.8yrsUS$86.31k0%
$ 0
Carolyn Beaver
Independent Director5.8yrsUS$86.31k0%
$ 0
Christopher Breder
Lead Scientific Advisory Boardless than a yearデータなしデータなし
Nicole Lemerond
Independent Director3yrsUS$86.31k0%
$ 0
6.5yrs
平均在職期間
68yo
平均年齢

経験豊富なボード: MNOVの 取締役会 は 経験豊富 であると考えられます ( 6.5年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/08/20 23:18
終値2026/08/20 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

MediciNova, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7

アナリスト機関
Lander Egaña-GorroñoH.C. Wainwright & Co.
Elemer PirosLucid Capital Markets
Jason McCarthyMaxim Group